机构地区:[1]西安交通大学第二附属医院急诊科,陕西西安710004
出 处:《西部医学》2017年第10期1401-1405,共5页Medical Journal of West China
基 金:陕西省科技攻关课题(2012K16-12-02)
摘 要:目的探讨乌司他丁联合奥曲肽对急性胰腺炎患者细胞因子的影响。方法选取2012年3月~2016年7月于本院接受治疗的126例急性胰腺炎患者,将所有患者随机分配到奥曲肽组、乌司他丁组及联合组,每组各42例。3组患者均进行常规治疗,奥曲肽组同时进行奥曲肽静脉泵注治疗,乌司他丁组同时进行乌司他丁静脉滴注治疗,联合组同时进行两种药物的联合用药治疗。回顾性分析3组患者的临床资料,观察分析3组患者治疗的临床疗效及对细胞因子的影响。结果 3组患者进行治疗后临床疗效的比较,奥曲肽组痊愈13例,有效14例,无效15例,总有效率为64.29%;乌司他丁组痊愈14例,有效12例,无效16例,总有效率为61.90%;联合组痊愈28例,有效11例,无效3例,总有效率为92.86%。联合组与奥曲肽组及乌司他丁组进行比较,3组临床疗效比较差异有统计学意义(P<0.05)。治疗前,3组进行细胞因子水平比较差异无统计学意义(P>0.05);治疗后,3组细胞因子水平比较差异有统计学意义(P<0.05);治疗后,奥曲肽组及乌司他丁组细胞因子水平进行对比,差异无统计学意义(P>0.05)。奥曲肽组并发症发生率为11.11%,乌司他丁组并发症发生率为7.93%,联合组并发症发生率为3.17%,三组比较差异有统计学意义(P<0.05)。结论乌司他丁联合奥曲肽治疗急性胰腺炎患者相比两种药物单纯治疗的临床疗效更显著,能够明显改善患者临床体征及症状,降低并发症的发生率,提高治疗的安全性,有利于患者病情快速恢复,值得临床推广。Objective To investigate the effect of ulinastatin combined with octreotide on cytokines in patients with acute pancreatitis. Methods 126 patients with acute pancreatitis admitted to our hospital from March 2012 to July 2016 were randomly divided into octreotide group, ulinastatin group and combined group. Each group consisted of 42 patients. The patients in the three groups were treated wi.th routine therapy. The octreotide group was given intravenous injection of octreotide. The ulinastatin group was treated with ulinastatin. The combination group was treated with the combina- tion of octreotide and ulinastatin. The clinica! data of 3 groups were retrospectively analyzed, and the clinical curative effect and cytokine effect were analyzed. Results In octreotide group, 13 cases were cured, 14 cases were effective and 15 cases were ineffective. The total effective rate of octreotide group was 64. 29%. In ulinastatin group, 14 cases were cured, 12 cases were effective and 16 cases were ineffective. The total effective rate of ulinastatin group was 61.90%. In combination group, 28 cases were cured, 11 cases were effective and 3 cases were ineffective. The total effective rate of combination group was 92.86%. The total effective rate the three groups were obviously difference (P〈0.05). The cy- tokines in the three groups before treatmeni Were not significantly different (P〉 0.05). The eytokines in the three groups after treatment were significantly different (P〈0. 05) group and combined group were 11.11%, 7.93% and 3.17%. group were statistically different from that of combined group. The complication rates of octreotide group, ulinastatin The complication rates of (P〈0.05). Conclusion octreotide group and ulinastatin Ulinastatin combined with oct-reotide in the treatment of acute panereatitis is effective in the treatment of acute pancreatitis. It can significantly improve the clinical signs and symptoms, reduce the incidence of complications and improve the safety of the treatment.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...